



Contact: Andrew Krouse
(434) 200-8442
krouse@cavionpharma.com
www.cavionpharma.com

Cavion Names Senior Scientific and Business Advisors

Llinas and Lynch Bring Decades of Neuroscience and Strategic Insight to Company

(Charlottesville, Va. -- February 1, 2016) [Cavion LLC](http://www.cavionpharma.com), a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of neurologic diseases and solid tumor cancers, announced today that Rodolfo Llinas, M.D., Ph.D has joined the company as scientific advisor and Daniel Lynch as strategic advisor. Both will work closely with Cavion's management team to advance and partner the company's platform of clinical stage assets.

"Cavion's greatest strength is our team, and we could not be more pleased to have advisors of Rodolfo and Dan's caliber join us during this critical next season," said Andrew Krouse, President and CEO of Cavion. "We are facing many important strategic decisions, and we plan to make use of both advisors' wisdom and expertise in driving Cavion to successful clinical and business outcomes."

Dr. Llinas is a member of the National Academy of Sciences and is the Thomas and Suzanne Murphy Professor of Neuroscience and former Chairman of the department of Physiology & Neuroscience at the New York University School of Medicine. He received his M.D from the Universidad Javeriana in Bogota, Columbia, and after postdoctoral training at Harvard and the University of Minnesota, he completed a Ph.D. in neurophysiology at the Australian National University (in Sir John Eccles' lab).

Dr. Llinas's research interest encompasses all levels of brain science, from ion channels to cognition. His study of human brain function using magnetoencephalography formed the basis for his discovery and introduction of thalamocortical dysrhythmia, an attribute of several neurological disorders. Thalamocortical dysrhythmias are observed in Essential Tremor, Parkinson's Disease, Pain, Epilepsy, Tinnitus, Schizophrenia and multiple rare and neuro-developmental diseases -- indications for which the Cavion platform may provide better treatment options.

Mr. Lynch currently serves as Venture Partner at Third Rock Ventures. He was previously the Executive Chairman of Avila Therapeutics (acquired by Celgene in 2012) and Stromedix (acquired by Biogen Idec in 2012). As CEO and CFO, he led ImClone Systems through a significant turnaround, helping to restore the company's reputation and to secure FDA approval of ERBITUX® (cetuximab), a novel cancer treatment. He currently leads the boards of Eleven Biotherapeutics, Blueprint Medicines, BIND Therapeutics, RaNA Therapeutics, and bluebirdbio. He received his M.B.A. from the Darden School of Business at the University of Virginia and his B.S. from Wesleyan University.

About Cavion LLC

Cavion LLC, founded as Tau Therapeutics LLC, is a privately held clinical stage platform pharmaceutical company creating therapies engaging the T-type calcium channel (Cav3) for the treatment of neurologic and oncologic diseases. The T-type calcium channel is an emerging molecular target for cancer and pain. Cavion intends to launch its first neurology clinical trial in 2016.

Cavion is co-sponsoring a [Phase 1 trial \(NCT02202993\)](#) of the T-type calcium channel blocker mibefradil combined with hypofractionated radiation therapy for the treatment of recurrent glioblastoma multiforme with the Yale University Comprehensive Cancer Center. A multi-site [NCI Adult Brain Tumor Consortium-sponsored Phase 1b clinical trial \(NCT01480050\)](#) of mibefradil administered with temozolomide in brain cancer has completed enrollment.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.